Galena Biopharma In (GALE) 2.15 $GALE
Galena Biopharma (GALE) is Overbought: Is A Drop Coming?
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 8:10AM CDT
Galena Biopharma, Inc. (GALE) has moved higher as of late, but there could definitely be trouble on the horizon for this company
GALE: 2.15 (-0.12)
Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
PR Newswire - Mon Jun 20, 7:25AM CDT
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
EBIO: 2.29 (-0.04), RLYP: 18.09 (+0.92), AMGN: 152.27 (+2.46), GALE: 2.15 (-0.12)
Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
GlobeNewswire - Mon Jun 13, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that combined safety data from the Company's GALE-401 clinical trials were presented at the European Hematology Association 21 Congress. GALE-401 is Galena's controlled release (CR) version of anagrelide for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce elevated platelet counts in patients suffering from myeloproliferative neoplasms (MPNs).
GALE: 2.15 (-0.12)
Galena Biopharma Receives Two Orphan Drug Designations for GALE-301 and GALE-301/GALE-302
GlobeNewswire - Fri Jun 10, 1:46PM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has granted two orphan-drug designations for Galena's two cancer immunotherapy peptides derived from Folate Binding Protein (FBP) for the treatment (including prevention of recurrence) of ovarian cancer: one for GALE-301 (E39), and one for GALE-301 (E39) and GALE-302 (E39'
. In clinical trials, GALE-301, and GALE-301/GALE-302 are combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF) for the treatment of ovarian cancer in the adjuvant setting.
GALE: 2.15 (-0.12)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Galena Biopharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Tue Jun 07, 6:12AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Galena Biopharma, Inc. (NASDAQ:GALE).
GALE: 2.15 (-0.12)
Galena Biopharma Presents GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016
GlobeNewswire - Mon Jun 06, 1:00PM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the primary analysis from the Company's GALE-301 Phase 1/2a clinical trial at the American Society of Clinical Oncology Annual Meeting 2016. GALE-301 is a cancer immunotherapy consisting of a peptide derived from Folate Binding Protein (FBP) combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF) for the prevention of cancer recurrence in ovarian and endometrial cancer patients in the adjuvant setting.
GALE: 2.15 (-0.12)
Small Cap Growth Isn't Slowing, Here's Proof
ACCESSWIRE - Thu Jun 02, 8:21AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / There's quite a lot of talk about small caps not delivering the sort of growth that they used to over the years but the truth is that many investors who hold this belief are simply not paying attention.
GALE: 2.15 (-0.12)
Galena Biopharma (GALE) in Focus: Stock Moves Up 19.3%
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:15AM CDT
Galena Biopharma, Inc. (GALE) shares rose over 19% in the last trading session.
HSKA: 34.55 (+0.65), GALE: 2.15 (-0.12)
Galena Biopharma Receives Fast Track Designation for NeuVax(TM) (nelipepimut-S) PRESENT Clinical Trial
GlobeNewswire - Wed Jun 01, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has designated NeuVax(TM) (nelipepimut-S), combined with recombinant granulocyte macrophage-colony stimulating factor (GM-CSF), as a Fast Track development program for the treatment of patients with early stage, node positive breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, following standard of care. Galena's PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial is an international, Phase 3 study to evaluate NeuVax plus GM-CSF versus placebo plus GM-CSF to prevent cancer recurrence.
GALE: 2.15 (-0.12)
Galena Biopharma to Present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum
GlobeNewswire - Tue May 24, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Sachs Associates 2 Annual Immuno-Oncology BD&L and Investment Forum. The presentation will take place on Friday, June 3, 2016 at 12:40 p.m. CT at the Hyatt Chicago Magnificent Mile Hotel in Chicago, IL.
GALE: 2.15 (-0.12)
6 Biotech Stocks That Will Heat Up Heading Into The Summer
ACCESSWIRE - Fri May 20, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 20, 2016 / As summer approaches, the weather continues getting hotter across the country and these 6 biotechnology companies could help investors surf a wave of profits from June to August.
GALE: 2.15 (-0.12)
Galena Biopharma to Present GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
GlobeNewswire - Thu May 19, 11:15AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that combined safety data from the Company's GALE-401 clinical trials will be presented at the upcoming European Hematology Association 21 Congress taking place June 9-12, 2016 in Copenhagen, Denmark. Details of the poster presentation are as follows:
GALE: 2.15 (-0.12)
Galena Biopharma to Present the GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016
GlobeNewswire - Wed May 18, 4:45PM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that the primary analysis from the Company's GALE-301 Phase 1/2a clinical trial will be presented at the upcoming American Society of Clinical Oncology Annual Meeting 2016, taking place June 3-7, 2016 in Chicago, IL. Details of the poster presentation are as follows:
GALE: 2.15 (-0.12)
Galena Biopharma Reports First Quarter 2016 Financial Results and Provides a Corporate Update
GlobeNewswire - Tue May 10, 4:09PM CDT
-- NeuVax(TM) (nelipepimut-S) Phase 3, PRESENT clinical trial reaches 70 qualifying disease free survival event
GALE: 2.15 (-0.12)
Sentnyl Therapeutics, Inc. Re-Launches Abstral® in the United States
PR Newswire - Tue May 03, 10:06AM CDT
Sentynl Therapeutics, Inc. ("Sentynl" announced that its commercial organization relaunched Abstral® in the United States. Sentynl acquired the rights to market Abstral® from Galena Biopharma in November 2015.
GALE: 2.15 (-0.12)
Galena Biopharma to Report First Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, May 10, 2016
GlobeNewswire - Wed Apr 27, 6:05AM CDT
Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that the Company will report its first quarter 2016 financial results and provide a corporate update on Tuesday, May 10, 2016 after the close of the financial markets. The company will host a conference call folllowing the announcement at 2:00 p.m. P.T./5:00 pm E.T. to discuss the financial and business results.
GALE: 2.15 (-0.12)
Galena Biopharma Appoints Mary Ann Gray, Ph.D., to Its Board of Directors
GlobeNewswire - Tue Apr 26, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the appointment of Mary Ann Gray, Ph.D. to the Company's Board of Directors effective immediately. Dr. Gray will be listed in Galena's 2016 Proxy and will be a nominee for election, at the Company's Annual Meeting of Stockholders.
GALE: 2.15 (-0.12)
Galena Biopharma Presents GALE-301/GALE-302 Clinical Booster Data at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 19, 8:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that data from the booster phase of the Company's GALE-301/GALE-302 Phase 1/2a clinical trial was presented at the American Association for Cancer Research (AACR) Annual Meeting.
GALE: 2.15 (-0.12)
Sirona Biochem Initiates Research and Development on New Therapies for Keloid Scars and Acne Vulgar
Marketwired - Mon Apr 18, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company" announces that its CEO, Dr. Howard Verrico, has approved two new therapeutic projects within the skin care portfolio addressing markets with unmet needs. Research and development will proceed for a novel compound for keloid scars and an acne treatment, each with a potentially favourable efficacy/side-effect-profile. Studies have begun for the keloid scar project with initial results expected in Q4 2016. The development program is being established for the acne program and will commence this quarter. The Company will look to partner the therapeutics after In-Vitro studies.
SBM.VN: 0.180 (unch), GALE: 2.15 (-0.12), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33), NVS: 80.67 (+0.96)
Galena Biopharma (GALE) is Overbought: Is A Drop Coming?
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 8:10AM CDT
Galena Biopharma, Inc. (GALE) has moved higher as of late, but there could definitely be trouble on the horizon for this company
GALE: 2.15 (-0.12)
Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
PR Newswire - Mon Jun 20, 7:25AM CDT
On Friday, June 17, 2016, the NASDAQ Composite ended the trading session at 4,800.34, down 0.92%; the Dow Jones Industrial Average edged 0.33% lower, to finish at 17,675.16; and the S&P 500 closed at 2,071.22, down 0.33%. However, five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Relypsa Inc. (NASDAQ: RLYP), Galena Biopharma Inc. (NASDAQ: GALE), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free trade alerts at:
EBIO: 2.29 (-0.04), RLYP: 18.09 (+0.92), AMGN: 152.27 (+2.46), GALE: 2.15 (-0.12)
Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
GlobeNewswire - Mon Jun 13, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that combined safety data from the Company's GALE-401 clinical trials were presented at the European Hematology Association 21 Congress. GALE-401 is Galena's controlled release (CR) version of anagrelide for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce elevated platelet counts in patients suffering from myeloproliferative neoplasms (MPNs).
GALE: 2.15 (-0.12)
Galena Biopharma Receives Two Orphan Drug Designations for GALE-301 and GALE-301/GALE-302
GlobeNewswire - Fri Jun 10, 1:46PM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has granted two orphan-drug designations for Galena's two cancer immunotherapy peptides derived from Folate Binding Protein (FBP) for the treatment (including prevention of recurrence) of ovarian cancer: one for GALE-301 (E39), and one for GALE-301 (E39) and GALE-302 (E39'
. In clinical trials, GALE-301, and GALE-301/GALE-302 are combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF) for the treatment of ovarian cancer in the adjuvant setting. GALE: 2.15 (-0.12)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Galena Biopharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Tue Jun 07, 6:12AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Galena Biopharma, Inc. (NASDAQ:GALE).
GALE: 2.15 (-0.12)
Galena Biopharma Presents GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016
GlobeNewswire - Mon Jun 06, 1:00PM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the primary analysis from the Company's GALE-301 Phase 1/2a clinical trial at the American Society of Clinical Oncology Annual Meeting 2016. GALE-301 is a cancer immunotherapy consisting of a peptide derived from Folate Binding Protein (FBP) combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF) for the prevention of cancer recurrence in ovarian and endometrial cancer patients in the adjuvant setting.
GALE: 2.15 (-0.12)
Small Cap Growth Isn't Slowing, Here's Proof
ACCESSWIRE - Thu Jun 02, 8:21AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / There's quite a lot of talk about small caps not delivering the sort of growth that they used to over the years but the truth is that many investors who hold this belief are simply not paying attention.
GALE: 2.15 (-0.12)
Galena Biopharma (GALE) in Focus: Stock Moves Up 19.3%
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:15AM CDT
Galena Biopharma, Inc. (GALE) shares rose over 19% in the last trading session.
HSKA: 34.55 (+0.65), GALE: 2.15 (-0.12)
Galena Biopharma Receives Fast Track Designation for NeuVax(TM) (nelipepimut-S) PRESENT Clinical Trial
GlobeNewswire - Wed Jun 01, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has designated NeuVax(TM) (nelipepimut-S), combined with recombinant granulocyte macrophage-colony stimulating factor (GM-CSF), as a Fast Track development program for the treatment of patients with early stage, node positive breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, following standard of care. Galena's PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial is an international, Phase 3 study to evaluate NeuVax plus GM-CSF versus placebo plus GM-CSF to prevent cancer recurrence.
GALE: 2.15 (-0.12)
Galena Biopharma to Present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum
GlobeNewswire - Tue May 24, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Sachs Associates 2 Annual Immuno-Oncology BD&L and Investment Forum. The presentation will take place on Friday, June 3, 2016 at 12:40 p.m. CT at the Hyatt Chicago Magnificent Mile Hotel in Chicago, IL.
GALE: 2.15 (-0.12)
6 Biotech Stocks That Will Heat Up Heading Into The Summer
ACCESSWIRE - Fri May 20, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 20, 2016 / As summer approaches, the weather continues getting hotter across the country and these 6 biotechnology companies could help investors surf a wave of profits from June to August.
GALE: 2.15 (-0.12)
Galena Biopharma to Present GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
GlobeNewswire - Thu May 19, 11:15AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that combined safety data from the Company's GALE-401 clinical trials will be presented at the upcoming European Hematology Association 21 Congress taking place June 9-12, 2016 in Copenhagen, Denmark. Details of the poster presentation are as follows:
GALE: 2.15 (-0.12)
Galena Biopharma to Present the GALE-301 Phase 1/2a Primary Analysis at the American Society of Clinical Oncology Annual Meeting 2016
GlobeNewswire - Wed May 18, 4:45PM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that the primary analysis from the Company's GALE-301 Phase 1/2a clinical trial will be presented at the upcoming American Society of Clinical Oncology Annual Meeting 2016, taking place June 3-7, 2016 in Chicago, IL. Details of the poster presentation are as follows:
GALE: 2.15 (-0.12)
Galena Biopharma Reports First Quarter 2016 Financial Results and Provides a Corporate Update
GlobeNewswire - Tue May 10, 4:09PM CDT
-- NeuVax(TM) (nelipepimut-S) Phase 3, PRESENT clinical trial reaches 70 qualifying disease free survival event
GALE: 2.15 (-0.12)
Sentnyl Therapeutics, Inc. Re-Launches Abstral® in the United States
PR Newswire - Tue May 03, 10:06AM CDT
Sentynl Therapeutics, Inc. ("Sentynl"
announced that its commercial organization relaunched Abstral® in the United States. Sentynl acquired the rights to market Abstral® from Galena Biopharma in November 2015. GALE: 2.15 (-0.12)
Galena Biopharma to Report First Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, May 10, 2016
GlobeNewswire - Wed Apr 27, 6:05AM CDT
Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that the Company will report its first quarter 2016 financial results and provide a corporate update on Tuesday, May 10, 2016 after the close of the financial markets. The company will host a conference call folllowing the announcement at 2:00 p.m. P.T./5:00 pm E.T. to discuss the financial and business results.
GALE: 2.15 (-0.12)
Galena Biopharma Appoints Mary Ann Gray, Ph.D., to Its Board of Directors
GlobeNewswire - Tue Apr 26, 6:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the appointment of Mary Ann Gray, Ph.D. to the Company's Board of Directors effective immediately. Dr. Gray will be listed in Galena's 2016 Proxy and will be a nominee for election, at the Company's Annual Meeting of Stockholders.
GALE: 2.15 (-0.12)
Galena Biopharma Presents GALE-301/GALE-302 Clinical Booster Data at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire - Tue Apr 19, 8:05AM CDT
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that data from the booster phase of the Company's GALE-301/GALE-302 Phase 1/2a clinical trial was presented at the American Association for Cancer Research (AACR) Annual Meeting.
GALE: 2.15 (-0.12)
Sirona Biochem Initiates Research and Development on New Therapies for Keloid Scars and Acne Vulgar
Marketwired - Mon Apr 18, 7:01AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company"
announces that its CEO, Dr. Howard Verrico, has approved two new therapeutic projects within the skin care portfolio addressing markets with unmet needs. Research and development will proceed for a novel compound for keloid scars and an acne treatment, each with a potentially favourable efficacy/side-effect-profile. Studies have begun for the keloid scar project with initial results expected in Q4 2016. The development program is being established for the acne program and will commence this quarter. The Company will look to partner the therapeutics after In-Vitro studies. SBM.VN: 0.180 (unch), GALE: 2.15 (-0.12), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33), NVS: 80.67 (+0.96)
